Literature DB >> 11801651

Functional avidity of tumor antigen-specific CTL recognition directly correlates with the stability of MHC/peptide multimer binding to TCR.

Valérie Dutoit1, Verena Rubio-Godoy, Marie-Agnès Doucey, Pascal Batard, Danielle Liénard, Donata Rimoldi, Daniel Speiser, Philippe Guillaume, Jean-Charles Cerottini, Pedro Romero, Danila Valmori.   

Abstract

Avidity of Ag recognition by tumor-specific T cells is one of the main parameters that determines the potency of a tumor rejection Ag. In this study we show that the relative efficiency of staining of tumor Ag-specific T lymphocytes with the corresponding fluorescent MHC class I/peptide multimeric complexes can considerably vary with staining conditions and does not necessarily correlate with avidity of Ag recognition. Instead, we found a clear correlation between avidity of Ag recognition and the stability of MHC class I/peptide multimeric complexes interaction with TCR as measured in dissociation kinetic experiments. These findings are relevant for both identification and isolation of tumor-reactive CTL.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11801651     DOI: 10.4049/jimmunol.168.3.1167

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Multiple costimulatory modalities enhance CTL avidity.

Authors:  James W Hodge; Mala Chakraborty; Chie Kudo-Saito; Charlie T Garnett; Jeffrey Schlom
Journal:  J Immunol       Date:  2005-05-15       Impact factor: 5.422

2.  Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells.

Authors:  Sixun Yang; Kwong-Yok Tsang; Jeffrey Schlom
Journal:  Clin Cancer Res       Date:  2005-08-01       Impact factor: 12.531

3.  Lentiviral calnexin-modified dendritic cells promote expansion of high-avidity effector T cells with central memory phenotype.

Authors:  Bei Wang; Shuhong Han; Lily Lien; Lung-Ji Chang
Journal:  Immunology       Date:  2009-09       Impact factor: 7.397

4.  Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting.

Authors:  Valérie Dutoit; Robert N Taub; Kyriakos P Papadopoulos; Susan Talbot; Mary-Louise Keohan; Michelle Brehm; Sacha Gnjatic; Paul E Harris; Brygida Bisikirska; Philippe Guillaume; Jean-Charles Cerottini; Charles S Hesdorffer; Lloyd J Old; Danila Valmori
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

5.  Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers.

Authors:  Maha Ayyoub; Danijel Dojcinovic; Pascale Pignon; Isabelle Raimbaud; Julien Schmidt; Immanuel Luescher; Danila Valmori
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-05       Impact factor: 11.205

6.  Nondominant CD8 T cells are active players in the vaccine-induced antitumor immune response.

Authors:  Jennifer N Uram; Chelsea M Black; Emilee Flynn; Lanqing Huang; Todd D Armstrong; Elizabeth M Jaffee
Journal:  J Immunol       Date:  2011-02-23       Impact factor: 5.422

7.  Cytotoxic T lymphocytes directed against a tumor-specific mutated antigen display similar HLA tetramer binding but distinct functional avidity and tissue distribution.

Authors:  Hamid Echchakir; Guillaume Dorothée; Isabelle Vergnon; Jeanne Menez; Salem Chouaib; Fathia Mami-Chouaib
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-01       Impact factor: 11.205

Review 8.  Mobilizing the low-avidity T cell repertoire to kill tumors.

Authors:  Rachel H McMahan; Jill E Slansky
Journal:  Semin Cancer Biol       Date:  2007-06-23       Impact factor: 15.707

Review 9.  Tricks with tetramers: how to get the most from multimeric peptide-MHC.

Authors:  Linda Wooldridge; Anna Lissina; David K Cole; Hugo A van den Berg; David A Price; Andrew K Sewell
Journal:  Immunology       Date:  2009-02       Impact factor: 7.397

10.  In vivo expansion of the residual tumor antigen-specific CD8+ T lymphocytes that survive negative selection in simian virus 40 T-antigen-transgenic mice.

Authors:  Todd D Schell
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.